Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like Despite One Death and One Adverse Event, bluebird bio's Gene Therapy Study Meets Goals October 4, 2017 <b>VenatoRx Pharma</b> Banks $42 Million to Advance Antibiotics Pipeline July 24, 2017 Realm Therapeutics Flunks PhII Trial for Conjunctivitis Drug March 11, 2018
Despite One Death and One Adverse Event, bluebird bio's Gene Therapy Study Meets Goals October 4, 2017
